Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 5Head & Neck 3Tumor-Agnostic 2Lymphoid 2Other solid neoplasm 1Dermatologic 1Breast 1

Conditions

Recurrence 1Lymphoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 139Rituximab 115Etoposide 77Vincristine 75Doxorubicin 62Cytarabine 61Dexamethasone 58Prednisone 55fludarabine 52Methotrexate 46N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 42Lenalidomide 37Gemcitabine 35Radiotherapy 29Melphalan 27pegaspargase 22Prednisolone 22Ifosfamide 22fludarabine phosphate 20Busulfan 20Cisplatin 19Bendamustine Hydrochloride 19Asparaginase 18Peripheral Blood Stem Cell Transplantation 17ibrutinib 16Decitabine 16Carmustine 16Mercaptopurine 15Filgrastim 15Oxaliplatin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × SHR-1701 × Lymphoid × Clear all
NCT04407741 2023-12-12

Phase â… /â…¡ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

Chinese PLA General Hospital

Phase 1/2 Unknown
100 enrolled
Lymphoid

Lymphoma

NCT05896046 2023-06-15

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Chinese PLA General Hospital

Phase 1/2 Unknown
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡